Fig. 1: Short-term (weeks 0–28) primary efficacy endpoints and quality of life assessments associated with high induction doses of risankizumab at weeks 0, 4, and 16. | Nature Communications

Fig. 1: Short-term (weeks 0–28) primary efficacy endpoints and quality of life assessments associated with high induction doses of risankizumab at weeks 0, 4, and 16.

From: A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab

Fig. 1: Short-term (weeks 0–28) primary efficacy endpoints and quality of life assessments associated with high induction doses of risankizumab at weeks 0, 4, and 16.

Open triangles below numbers represent doses of risankizumab. a PASI 75 responses. b PASI 90 responses. c PASI 100 responses. d DLQI 0/1 responses at week 28. Data are presented as mean ± 95% confidence interval.

Back to article page